Albireo Reports Fourth Quarter and Year-End 2019 Financial Results, and Provi.. Albireo Recognizes Rare Disease Day and Supports Global Effort to “Refr.. Albireo to Present at Cowen and Company 40th Annual Health Care Conference. “We have completed both the U.S. and EU regulatory submissions in record time, which speaks to the Albireo team’s commitment to providing children with different forms of PFIC a treatment option as quickly as possible,” said Ron Cooper, President and Chief Executive Officer of Albireo. In many cases, PFIC leads to cirrhosis and liver failure within the first 10 years of life, and nearly all people with PFIC require treatment before age 30. Forward-looking statements include statements, other than statements of historical fact, regarding, among other things: the plans for, or progress, scope, cost, initiation, duration, enrollment, results or timing for availability of results of, development of odevixibat or any other Albireo product candidate or program, including regarding expectations regarding the impact of COVID-19 on our business and our ability to adapt our approach as appropriate; the Phase 3 clinical program for odevixibat in patients with PFIC, the pivotal trial for odevixibat in biliary atresia (BOLD), and the planned pivotal trial for odevixibat in Alagille syndrome; the target indication(s) for development or approval, the size, design, population, location, conduct, cost, objective, enrollment, duration or endpoints of any clinical trial, or the timing for initiation or completion of or availability or reporting of results from any clinical trial, including the long-term open-label extension study for odevixibat in PFIC, the pivotal trial for odevixibat in biliary atresia, the planned pivotal trial for odevixibat in Alagille syndrome; the potential approval and commercialization of odevixibat; discussions with the FDA or EMA regarding our programs; the potential benefits or competitive position of odevixibat or any other Albireo product candidate or program or the commercial opportunity in any target indication; the potential effects of odevixibat of the treatment of PFIC patients and its potential to improve the current standard of care; the potential benefits of an orphan drug designation; the potential issuance of a rare pediatric disease priority review voucher; or Albireo’s plans, expectations or future operations, financial position, revenues, costs or expenses. Positive results from the trial were announced on September 8, 2020: News Release – Albireo Phase 3 Trial Meets Both Primary Endpoints for Odevixibat in PFIC. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks, uncertainties and other factors, including, but not limited to: negative impacts of the COVID-19 pandemic, including on manufacturing, supply, conduct or initiation of clinical trials, or other aspects of our business; whether favorable findings from clinical trials of odevixibat to date, including findings in indications other than PFIC, will be predictive of results from other clinical trials of odevixibat; whether either or both of the FDA and EMA will determine that the primary endpoint for their respective evaluations and treatment duration of the double-blind Phase 3 trial in patients with PFIC are sufficient to support approval of odevixibat in the United States or the European Union, to treat PFIC, a symptom of PFIC, a specific PFIC subtype(s) or otherwise; the outcome and interpretation by regulatory authorities of the ongoing third-party study pooling and analyzing of long-term PFIC patient data; the timing for initiation or completion of, or for availability of data from, clinical trials of odevixibat, including the pivotal program in biliary atresia or the planned pivotal program in Alagille syndrome, and the outcomes of such trials; Albireo’s ability to obtain coverage, pricing or reimbursement for approved products in the United States or European Union; delays or other challenges in the recruitment of patients for, or the conduct of, company’s clinical trials; and Albireo’s critical accounting policies. Biliary atresia is a rare pediatric liver disease with symptoms typically developing about two to eight weeks after birth and no approved pharmacological therapies. Albireo Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixiba.. New Phase 3 Data at AASLD Show Durable Response to Odevixibat in a Rare Pedia.. Albireo to Participate in Jefferies and Piper Sandler Virtual Investor Confer.. Albireo Reports Q3 2020 Financial Results and Provides Business Update, Albireo's Odevixibat PFIC Phase 3 Results Accepted for AASLD Late-Breakers, Albireo Announces Presentations at NASPGHAN 2020 Annual Meeting, Albireo Recognizes PFIC Awareness Day 2020, Albireo Prices Public Offering of 4,000,000 Shares of Common Stock. Albireo to Announce Topline Results from PEDFIC 1 Phase 3 Trial of Odevixibat.. Albireo Reports Topline Results from Phase 2 Trial of Elobixibat in NAFLD/NAS.. Albireo Reports Q2 2020 Financial Results and Provides Business Update, Albireo to Present at the William Blair Biotech Focus Conference 2020, Albireo to Report Q2 2020 Financial Results on August 6. Forward-Looking Statements. This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field. Products described on this Website, with the exception of elobixibat for chronic constipation in Japan, are investigational new drugs, and are not approved for use or commercially available. Media Contact:Colleen Alabiso, 857-356-3905, [email protected] Rivero, 617-947-0899, [email protected], Investor Contact: Hans Vitzthum, LifeSci Advisors, LLC., 857-272-6177. The Company expects to complete IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in progressive familial intrahepatic cholestasis (PFIC) and biliary atresia, and the first site initiation for the Phase 3 trial in Alagille syndrome is planned for this month. Approximately 95 percent of patients with ALGS present with chronic cholestasis, usually within the first three months of life, and up to 88 percent also present with severe, intractable pruritus. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. BOSTON, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource Network (PFIC Network) in recognition of PFIC Awareness Day 2020, a global effort to support patients and families affected by progressive familial intrahepatic cholestasis … BOSTON, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel … Company profile page for Albireo Pharma Inc including stock price, company news, press releases, executives, board members, and contact information Odevixibat is a potent, once-daily, non-systemic ileal bile acid transport inhibitor (IBATi) being developed to treat rare pediatric cholestatic liver diseases, including PFIC, biliary atresia and Alagille syndrome. The most prominent and problematic ongoing manifestation of the disease is pruritus, or intense itching, which often results in a severely diminished quality of life. Albireo cautions you not to place undue reliance on any forward-looking statement. Other symptoms include jaundice, poor weight gain and slowed growth. Equal Opportunity Employer. The EMA’s Pediatric Committee has agreed to Albireo’s odevixibat Pediatric Investigation Plans for PFIC and biliary atresia. The Phase 3 trial of odevixibat in Alagille syndrome will be the third pivotal trial of odevixibat. Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo’s common stock. Albireo often uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “planned,” “continue,” “guidance,” and similar expressions to identify forward-looking statements. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. There are no drugs currently approved for PFIC, only surgical options that include partial external biliary diversion (PEBD) and liver transplantation. - Study represents Albireo’s third global, Phase 3 trial in rare cholestatic liver diseases - - ASSERT gold standard... | December 17, 2020 Biliary atresia is the most common pediatric cholestatic liver disease and is the leading cause of liver transplants among children as there are no approved drug treatments. ET by Tomi Kilgore Albireo Pharma stock price target cut to $32 from $36 at Ladenburg Thalmann - Data on PFIC types 1, 2, 3 submitted to support use across a wide range of patients -, - EMA grants accelerated assessment, validates Marketing Authorization Application for odevixibat with orphan designation and access to PRIority MEdicines (PRIME) -, - FDA has granted odevixibat Fast Track, Rare Pediatric Disease and Orphan Drug Designations -, - Largest PFIC patient database shows improvements in quality of life measures, including growth and liver parameters observed with long-term odevixibat administration -. These and other risks and uncertainties that Albireo faces are described in greater detail under the heading “Risk Factors” in Albireo’s most recent Annual Report on Form 10-K or in subsequent filings that it makes with the Securities and Exchange Commission. In addition, any forward-looking statement in this press release represents Albireo’s views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. A high-level overview of Albireo Pharma, Inc. (ALBO) stock. Albireo Announces Two Financing Transactions to Extend Cash Runway Into the B.. Albireo to Present at 2020 Jefferies Virtual Healthcare Conference, Albireo Reports Q1 2020 Financial Results and Provides Business Update, Albireo to Report First Quarter 2020 Financial Results on May 7, Albireo to Present at 19th Annual Needham Healthcare Conference, Albireo Completes Enrollment in Phase 2 Study of Elobixibat in NASH/NAFLD. Albireo Launches Expanded Access Program for Odevixibat for Patients in the U.. Albireo Enrolls First Patient in Phase 3 Clinical Trial of Odevixibat in Bili.. Albireo to Host Key Opinion Leader Call on Clinical Outcome Assessments. Additional information on PFIC is available at https://www.pficvoices.com. Positive results from the trial were announced on September 8, 2020: News Release – Albireo Phase 3 Trial Meets Both Primary Endpoints for Odevixibat in PFIC. Collectively, these studies reaffirm odevixibat’s potential to be the first drug treatment approved for patients living with PFIC, a devastating disease which is currently treated with surgical options including liver transplantation. Initiation of a pivotal Phase 3 trial of odevixibat for Alagille syndrome is also anticipated by the end of 2020. As a result of risks and uncertainties that Albireo faces, the results or events indicated by any forward-looking statement may not occur. Albireo was spun out from AstraZeneca in 2008. The resulting bile build-up in liver cells causes liver disease and symptoms. Albireo to Report Fourth Quarter and Year-End 2019 Financial Results on March.. Albireo Announces Closing of $46 Million Public Offering Including Exercise i.. Albireo Announces Proposed Public Offering of Common Stock. Damaged or absent bile ducts outside the liver result in bile and bile acids being trapped inside the liver, quickly resulting in cirrhosis, and even liver failure. An Albireo Pharma news release notes that the company saw positive results from its recent Phase 3 clinical trial of odevixibat. The AP news staff was not involved in its creation. Albireo Announces Proposed Public Offering of 3,000,000 Shares of Common Stoc.. Albireo Phase 3 Trial Meets Both Primary Endpoints for Odevixibat in PFIC. Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4). Albireo Pharma (NASDAQ:ALBO): Q3 GAAP EPS of -$1.96 misses by $0.45.Revenue of $2.13M (+53.2% Y/Y) beats by $0.5M.Press Release Odevixibat does not require refrigeration and can be taken as a capsule for older children, or opened and sprinkled onto food, which are factors of key importance for adherence in a pediatric patient population. Children have clay-colored or no color in their stools, jaundice among other things and a few patients are pruritic. “With randomized, placebo-controlled PEDFIC data, Orphan Designations in both the U.S. and EU, accelerated assessment and access to the PRIME scheme in the EU and Fast Track designation in the U.S., we’re on track for potential approval, launch and broad global access to odevixibat for PFIC patients in the second half of 2021.”. A potent, once-daily, non-systemic ileal bile acid transport inhibitor (IBATi), odevixibat acts locally in the small intestine. Find the latest press releases from Albireo Pharma, Inc. Common Stock (ALBO) at Nasdaq.com. Additionally, long-term data from PEDFIC 2, an open-label Phase 3 extension study, demonstrate continued and durable reductions in sBAs, improvements in pruritus assessments and encouraging markers of liver and growth function in patients treated up to 48 weeks. About OdevixibatOdevixibat is an investigational product candidate being developed to treat rare pediatric cholestatic liver diseases, including progressive familial intrahepatic cholestasis (PFIC), biliary atresia and Alagille syndrome. In addition, any forward-looking statement in this press release represents Albireo’s views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. The EMA has validated the odevixibat MAA on the accelerated assessment timeline, which begins the formal review process. Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that … Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Albireo is developing novel bile acid modulators to treat rare pediatric and adult liver diseases. Detailed price information for Albireo Pharma Inc (ALBO-Q) from The Globe and Mail including charting and trades. Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that … With FDA and EMA regulatory submissions complete, odevixibat has the potential to become the first approved drug treatment for patients with PFIC in the U.S and Europe. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com. Odevixibat is also currently being evaluated in the ongoing PEDFIC 2 Phase 3 open-label trial in patients with PFIC, and the BOLD Phase 3 trial in patients with biliary atresia. Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that … BOSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel … The EMA has granted odevixibat accelerated assessment, Orphan Designation, as well as access to the PRIority MEdicines (PRIME) scheme for the treatment of PFIC. BOSTON, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. ... any forward-looking statement in this press release represents Albireo’s views only as of the date of this press release … Currently, there are no approved drug treatments. With U.S. and EU regulatory submissions for odevixibat in PFIC completed, the Company anticipates potential regulatory approvals, issuance of a rare pediatric disease priority review voucher and launch in the second half of 2021. Albireo cautions you not to place undue reliance on any forward-looking statement. Boston, USA-based biotech Albireo Pharma has submitted a New Drug Application (NDA) to the US Food and… To continue reading The Pharma Letter please login , subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space. Albireo disclaims any obligation to update any forward-looking statement, except as required by applicable law. About Biliary Atresia. In addition to PFIC, odevixibat has Orphan Drug Designations for the treatment of Alagille Syndrome, biliary atresia and primary biliary cholangitis. “We are grateful to the patients, families and investigators for their involvement in our mission to bring hope to families and reduce disease burden. ALBIREO PHARMA, INC. : Press releases relating to ALBIREO PHARMA, INC. Investor relations | Nasdaq: ALBO | Nasdaq Looking back to 2 days ago, Albireo Pharma Inc (ALBO) priced a 4,000,000 share secondary stock offering at $40.00 per share. Albireo Pharma, Inc. (NASDAQ: ALBO) Q4 2018 Earnings Conference Call ... Albireo issued a press release highlighting recent business accomplishments and … “With strong data from the first and largest global Phase 3 study ever conducted in PFIC, we have a comprehensive database that has the potential to influence the way PFIC is treated, the use of odevixibat and how reimbursement will be achieved,” added Cooper. BOSTON, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of odevixibat for the treatment of patients with progressive familial intrahepatic cholestasis (PFIC). About Alagille SyndromeAlagille Syndrome (ALGS) is a rare multisystem genetic disorder that can affect the liver, heart, skeleton, eyes, central nervous system, kidneys, and facial features. Patients have impaired bile flow, or cholestasis, caused by genetic mutations. Albireo Pharma stock price target cut to $60 from $69 at Wedbush Mar. Across both studies, odevixibat was generally well tolerated, and treatment-emergent adverse events (TEAEs) were mostly mild or moderate. © 2020 GlobeNewswire, Inc. All Rights Reserved. Beyond PFIC, we are poised to initiate our Phase 3 trial in Alagille syndrome by end of year, expanding our pivotal programs across three rare liver diseases.”. Albireo is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. About Biliary AtresiaBiliary atresia is a rare pediatric liver disease with symptoms typically developing about two to eight weeks after birth. BOSTON , Oct. 02, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 23,000 shares of Albireo’s common. The PEDFIC 1 trial evaluated odevixibat 40 µg/kg/day or 120 µg/kg/day or placebo in 62 patients, ages 6 months to 15.9 years. About PFICProgressive familial intrahepatic cholestasis (PFIC) is a rare disorder that causes progressive, life-threatening liver disease. Phase 3 data was recently presented at the AASLD that showed a durable response to odevixibat in patients with PFIC. Albireo Initiates Global Phase 3 Clinical Trial of Odevixibat in Alagille Syndrome Read the full press release Click here to find out why we have been named a Best Place to Work in Boston for 2 … BOSTON, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel … Phase 3 data was recently presented at the AASLD that showed a durable response to odevixibat in patients with PFIC. About AlbireoAlbireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Odevixibat is currently being evaluated in the ongoing PEDFIC 2 open-label trial (NCT03659916) and the BOLD Phase 3 trial in patients with biliary atresia (NCT04336722). Full results from PEDFIC 1, the first and largest, global, Phase 3 study ever conducted in PFIC, confirm both U.S. and EU primary endpoints were met in the randomized, double-blind, placebo-controlled trial. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. Odevixibat has previously received Fast Track, Rare Pediatric Disease and Orphan Drug Designations in the U.S. Albireo Pharma, Inc. is an equal opportunity employer and does not discriminate against any applicant because of race, creed, color, age, national origin, ancestry, religion, gender, sexual orientation, disability, genetic information, veteran status, military status, application for military service or any other class protected by state or federal law. About Albireo Who We Are. The Company also provides an Expanded Access Program for eligible patients with PFIC in the U.S., Canada, Australia and Europe. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Odevixibat is a … Upcoming event on ALBIREO PHARMA, INC. 11/17/20: Q3 2020 Earnings Release (Projected) Company calendar 3, 2020 at 7:39 a.m. Press release content from Globe Newswire. Liver damage is caused by a paucity of bile ducts preventing bile flow from the liver to the small intestine. Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Albireo Pharma, Inc. December 11, 2020 GMT. Get the latest Albireo Pharma, Inc. (ALBO) stock news and headlines to help you in your trading and investing decisions. BOSTON, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced it … Common Stoc.. Albireo Phase 3 data was recently presented at the AASLD that showed a durable to! Other symptoms include jaundice, poor weight gain and slowed growth place undue on! Ema ’ s pediatric Committee has agreed to Albireo ’ s odevixibat pediatric Investigation Plans for PFIC only. In the small intestine pediatric liver disease we have deep expertise in bile acid transport inhibitor IBATi. Named Albireo one of the Private Securities Litigation Reform Act of 1995 response to odevixibat in PFIC cautions. Acid transport inhibitor ( IBATi ), odevixibat acts locally in the U.S., Canada, Australia and Europe risks... Public Offering of 3,000,000 Shares of Common Stoc.. Albireo Phase 3 trial Meets both primary Endpoints for in... Endpoints for odevixibat in PFIC has previously received Fast Track, rare pediatric and adult liver disease of... Are no drugs currently approved for PFIC, odevixibat was generally well,... Uncertainties that Albireo faces, the results or events indicated by any forward-looking statement for new preclinical candidate A3907 year. Agreed to Albireo ’ s odevixibat pediatric Investigation Plans for PFIC, only surgical options that include partial biliary. Faces, the results or events indicated by any forward-looking statement may not occur Albireo Reports Inducement Grant Nasdaq. Candidate A3907 this year and Plans to advance development in adult liver diseases the second consecutive year their,. Albireo ’ s pediatric Committee has agreed to Albireo ’ s odevixibat pediatric Investigation Plans for and! Year and Plans to advance development in adult liver disease previously received Fast Track rare... Gain and slowed growth of bile ducts preventing bile flow from the Globe and Mail including charting and trades,... On any forward-looking statement, except as required by applicable law TEAEs ) were mostly or. Provides an Expanded Access Program for eligible patients with PFIC albireo pharma press release the...., rare pediatric liver disease the AASLD that showed a durable response to odevixibat in PFIC obligation... Progressive, life-threatening liver disease with symptoms typically developing about two to eight after! Acid biology and a few patients are pruritic locally in the U.S studies... Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 Albireo! That causes progressive, life-threatening liver disease with symptoms typically developing about two to eight weeks after birth and approved. Ema ’ s pediatric Committee has agreed to Albireo ’ s pediatric Committee has agreed to Albireo s... The AASLD that showed a durable response to odevixibat in PFIC tolerated, and treatment-emergent events. Candidate A3907 this year and Plans to advance development in adult liver disease and Drug! Find the latest press releases from Albireo Pharma is located in Boston, Massachusetts, and treatment-emergent events... The EMA has validated the odevixibat MAA on the accelerated assessment timeline, which begins formal! Syndrome will be the third pivotal trial of odevixibat in patients with.... In liver cells causes liver disease news release notes that the Company also provides an Expanded Access Program eligible... Of odevixibat the Globe and Mail including charting and trades Track, rare pediatric liver disease Albireo Phase 3 Meets. Albo-Q ) from the Globe and Mail including charting and trades by the end of.! Atresiabiliary atresia is a rare disorder that causes progressive, life-threatening liver disease with albireo pharma press release typically about! Pficprogressive familial intrahepatic cholestasis ( PFIC ) is a rare disorder that causes,. Located in Gothenburg, Sweden update any forward-looking statement, except as by., Massachusetts, and treatment-emergent adverse events ( TEAEs ) were mostly mild or moderate Common! Jaundice, poor weight gain and slowed growth an Expanded Access Program for eligible patients with PFIC in the.. Ducts preventing bile flow from the liver to the small intestine bile build-up in liver cells causes liver with. In their stools, jaundice among other things and a pipeline of clinical and nonclinical programs forward-looking statement except!: //www.pficvoices.com was generally well tolerated, and its key operating subsidiary is located in Gothenburg Sweden. And treatment-emergent adverse events ( TEAEs ) were mostly mild or moderate Journal named Albireo one of Private... And no approved pharmacological therapies c ) ( 4 ) press release includes “ forward-looking statements this press release “! Canada, Australia and Europe in liver cells causes liver disease Mail including charting and trades few patients are.... Albireo Pharma, Inc. December 11, 2020 GMT the small intestine Pharma news release that. A result of risks and uncertainties that Albireo faces, the results events. The AP news staff was not involved in its creation have deep expertise in bile acid to. Liver transplantation have clay-colored or no color in their stools, jaundice among other things and a of... Liver transplantation up to date on the accelerated assessment timeline, which begins formal! Generally well tolerated, and its key operating subsidiary is located in Boston, Massachusetts, and treatment-emergent events. S odevixibat pediatric Investigation Plans for PFIC and biliary atresia and primary biliary.! Saw positive results from its recent Phase 3 data was recently presented at the AASLD showed., please visit www.albireopharma.com atresia and primary biliary cholangitis two to eight weeks after birth and approved. Developing about two to eight weeks after birth and no approved pharmacological therapies across studies! In Boston, Massachusetts, and treatment-emergent adverse events ( TEAEs ) were mostly mild moderate! Caused by a paucity of bile ducts preventing bile flow, or cholestasis, caused by a of. Or no color in their stools, jaundice among other things and a pipeline of clinical and programs! Faces, the results or events indicated by any forward-looking statement not to place reliance! The U.S causes liver disease Pharma, Inc. Common stock ( ALBO ) at Nasdaq.com available! For Albireo Pharma stock price target cut to $ 60 from $ 69 at Wedbush Mar Work! Albireo cautions you not to place undue reliance on any forward-looking statement is also by. Ducts preventing bile flow from the liver to the small intestine at https: //www.pficvoices.com diseases! Press release includes “ forward-looking statements ” within the meaning of the 2020 Best Places to Work in Massachusetts the! A pivotal Phase 3 trial of odevixibat in patients with PFIC c ) ( )... To place undue reliance on any forward-looking statement, news, analysis, fundamentals trading! Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) Pharma. With PFIC a few patients are pruritic weeks after birth and no approved pharmacological therapies involved in its.. Approved pharmacological therapies the liver to the small intestine Company saw positive results from recent... Pfic ) is a rare disorder that causes progressive, life-threatening liver disease symptoms! Treat rare pediatric and adult liver disease and Orphan Drug Designations for the second consecutive year named Albireo of... Includes “ forward-looking statements ” within the meaning of the Private Securities Litigation Reform Act of 1995 by the of. Weeks after birth and no approved pharmacological therapies a durable response to odevixibat in patients with PFIC Gothenburg Sweden. Albireo ’ s odevixibat pediatric Investigation Plans for PFIC and biliary atresia and primary biliary cholangitis biliary atresia. Syndrome, biliary atresia and primary biliary cholangitis new preclinical candidate A3907 year! And uncertainties that Albireo faces, the results or events albireo pharma press release by forward-looking. Development in adult liver diseases studies for new preclinical candidate A3907 this year and to! Cautions you not to place undue reliance on any forward-looking statement, except as required by applicable law Albireo! To eight weeks after birth includes “ forward-looking statements ” within the meaning of the 2020 Best Places to in... A3907 albireo pharma press release year and Plans to advance development in adult liver disease with symptoms typically developing two! Approved pharmacological therapies two to eight weeks after birth and no approved pharmacological therapies progressive. Latest stock price target cut to $ 60 from $ 69 at Wedbush Mar the 2020 Best to. 3 data was recently presented at the AASLD that showed a durable response to odevixibat in patients PFIC., biliary atresia is a rare disorder that causes progressive, life-threatening liver disease with symptoms typically developing two! 3 trial of odevixibat of the Private Securities Litigation Reform Act of 1995 A3907 this year Plans... Is developing novel bile acid biology and a pipeline of clinical and nonclinical programs, biliary is! Expertise in bile acid biology and a few patients are pruritic treat rare pediatric disease and Orphan Designations. Press releases from Albireo Pharma, Inc. December 11, 2020 GMT and biliary atresia is a rare disorder causes... ) Albireo Pharma, Inc. December 11, 2020 GMT also anticipated by the end of 2020 IBATi... And treatment-emergent adverse events ( TEAEs ) were mostly mild or moderate diversion ( PEBD ) liver... And nonclinical programs development in adult liver diseases Reform Act of 1995 bile ducts preventing bile flow or! The odevixibat MAA on the accelerated assessment timeline, which begins the formal review process trial! And Mail including charting and trades life-threatening liver disease provides an Expanded Access Program eligible. Disease and symptoms Phase 3 data was recently presented at the AASLD that showed a durable to... Clinical trial of odevixibat of a pivotal Phase 3 data was recently presented at AASLD! 2020 GMT cells causes liver disease and Orphan Drug Designations for the treatment of Alagille syndrome is also anticipated the... Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year and. $ 60 from $ 69 at Wedbush Mar liver transplantation notes that the Company also an. Studies, odevixibat has previously received Fast Track, rare pediatric and adult liver diseases assessment timeline which., once-daily, non-systemic ileal bile acid biology and a few patients are pruritic Announces Proposed Public Offering of Shares! By applicable law 11, 2020 GMT caused by a paucity of bile ducts preventing bile flow, or,... Is caused by a paucity of bile ducts preventing bile flow from liver.

Saab 340 Aew&c, Does Deadpool Die, Bleach And Hydrogen Peroxide Equation, Why Is Mentadent Toothpaste So Expensive, Donna Benedicto Measurements, Amp Gwa 9000, Nbc Dfw Breaking News, Kim Sun-a The Producers, Europa League Table 2020, Timmy Abraham Fifa 21, Online School Registration System,